KPTI:NASDAQ, Karyopharm Therapeutics Inc.

Why KPTI stock rose on November 12

Karyopharm Therapeutics Inc. rose 46.6% on Thursday, November 12, 2026, on 2,711,602 shares. No headline about KPTI came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

KPTI stock overview

Karyopharm Therapeutics Inc. (KPTI:NASDAQ) closed at $0.017 on November 10, 2026, unchanged on the day. The stock trades 99.8% below its 52-week high of $10.99 and 117.5% above its 52-week low of $0.008. Over the past year, it lost 99.7%. Karyopharm Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price
$0.017
Day change
0.00%
Volume
136,647,057
Average volume
8,655,195
Market cap
394K+
52-week range
$0.008 – $10.99
50-day average
$0.853
200-day average
$5.71

Price action over the past year

In 252 trading sessions since November 14, 2025, KPTI closed higher on 117 days (46%). Its best day was October 28, 2026 (+73.33%) and its worst was November 2, 2026 (-83.08%). The stock moved 10% or more in a single session 34 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

KPTI news

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases....

Similar stocks

Find more stocks like KPTI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.